SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Windlas Biotech - Quaterly Results

09 Sep 2021 Evaluate
A fair growth of 8.49% in the revenue at Rs. 1109.56 millions was reported in the June 2021 quarter as compared to Rs. 1022.77 millions during year-ago period.The Total Profit for the quarter ended June 2021 of Rs. 66.87 millions grew from Rs.-226.05 millionsOperating profit for the quarter ended June 2021 decreased to 130.74 millions as compared to 145.54 millions of corresponding quarter ended June 2020.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202106 202006 % Var 202106 202006 % Var 202106 202006 % Var
Sales 1109.56 1022.77 8.49 1109.56 1022.77 8.49 1109.56 1022.77 8.49
Other Income 6.89 6.91 -0.29 6.89 6.91 -0.29 6.89 6.91 -0.29
PBIDT 130.74 145.54 -10.17 130.74 145.54 -10.17 130.74 145.54 -10.17
Interest 4.82 2.54 89.76 4.82 2.54 89.76 4.82 2.54 89.76
PBDT 125.92 -180.51 -169.76 125.92 -180.51 -169.76 125.92 -180.51 -169.76
Depreciation 30.25 29.84 1.37 30.25 29.84 1.37 30.25 29.84 1.37
PBT 95.67 -210.35 -145.48 95.67 -210.35 -145.48 95.67 -210.35 -145.48
TAX 28.80 15.70 83.44 28.80 15.70 83.44 28.80 15.70 83.44
Deferred Tax -0.07 15.70 -100.45 -0.07 15.70 -100.45 -0.07 15.70 -100.45
PAT 66.87 -226.05 -129.58 66.87 -226.05 -129.58 66.87 -226.05 -129.58
Equity 91.04 64.11 42.01 91.04 64.11 42.01 91.04 64.11 42.01
PBIDTM(%) 11.78 14.23 -17.20 11.78 14.23 -17.20 11.78 14.23 -17.20

Windlas Biotech Share Price

865.40 -6.35 (-0.73%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×